The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...

George Tidmarsh, the newly installed director of the FDA’s Center for Drug Evaluation and Research, was placed on leave ...

Q3 2025 Earnings Call Transcript November 4, 2025 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...

Less than 24 hours after resigning his post as the FDA’s head drug regulator, George Tidmarsh is reportedly reconsidering his decision and vowing to fight for his name and credibility amid a probe ...

Hilliard, the HHS spokesperson, told SFGATE on Tuesday that, “Secretary [Robert F.] Kennedy [Jr.] expects the highest ethical ...

Aurinia Pharmaceuticals (AUPH) stock slips as RBC Capital Markets downgrades the company following its better than expected ...

A lawsuit filed against George Tidmarsh, who resigned from a top FDA post on Sunday, includes a series of incendiary texts and emails ...

Jefferies upgraded Aurinia Pharmaceuticals (AUPH) to Buy from Hold with a price target of $21, up from $10. The company’s commercial performance ...

The top drug regulator at the Food and Drug Administration (FDA) resigned Sunday, according to officials, after being accused ...

An alleged extortion attempt, a petty yearslong grudge, shocking social media posts, and ominous text messages make up the ...

Aurinia Pharmaceuticals (AUPH) has swung into profitability over the past year, with earnings climbing at an impressive 43.8% per year on average for the past five years. Investors have watched as ...

Reports suggest that, internally, the Food and Drug Administration is facing a crisis of confidence.